ESLA ESLA
Company Profile ↓Company Overview
ESLA (ESLA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 126.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 126.0%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -9.78% |
| 6 Months: | -36.15% |
| 3 Months: | -46.91% |
| 1 Month: | -17.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 126.0%.
- Healthy ROCE of 126.0%.
CONS
- Trading 75.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -819 | -3.56K | -108.11K | -144.94K | -423.76K | -2.89M | -2.76M | -2.74M | -169.24K | -1.87M | -1.02M | -469.53K | -3.95M | -3.38M | -2.10M | -5.54M | -4.80M | -2.29M |
| Net Income | -819 | -3.56K | -107.55K | -141.25K | -359.59K | -2.89M | -2.76M | -2.74M | -76.00K | -1.87M | -1.02M | -469.53K | -3.95M | -3.38M | -2.10M | -5.54M | -4.80M | -2.29M |
| Diluted EPS | 0.00 | 0.00 | -0.99 | -0.02 | -0.06 | -34.33 | -16.33 | -8.13 | - | -1.78 | -0.03 | -0.01 | -0.11 | -0.09 | -0.06 | -0.15 | -0.13 | -0.05 |
| R&D Expense | - | - | - | - | - | 2.61M | 2.61M | 2.62M | - | 483.47K | 75.46K | 25.00K | 3.52M | 2.83M | 1.41M | 4.66M | 4.15M | 1.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -249.15K | -1.57M | -11.11M | -7.31M | -13.06M |
| Net Income | -247.72K | -996.10K | -11.11M | -7.31M | -13.06M |
| Diluted EPS | - | - | -36.35 | -0.27 | -0.35 |
| R&D Expense | - | - | 10.45M | 4.11M | 10.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 45.80M | - | 9.72M | 3.03M | 4.45M | 3.14M | 3.18M |
| Total Equity | 0 | -1.01M | -1.04M | -2.26M | -11.74M | 4.27M | 143.73K | -10.37M |
| Cash & Equivalents | - | 478.87K | - | 40.80K | 2.48M | 4.17M | 916.92K | 1.38M |
| Total Liabilities | - | 1.62M | - | 2.65M | 9.77M | 180.70K | 3.00M | 13.54M |
| Current Liabilities | - | 73.15K | - | 1.07M | 9.76M | 180.70K | 3.00M | 13.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -316.16K | -1.04M | -1.34M | -16.07M | -1.79M |
| Investing Cash Flow | -45.19M | 36.17M | -273.07K | 4.96M | - |
| Financing Cash Flow | 45.98M | -35.56M | - | 12.79M | 2.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | 24.6% | 44.2% | 94.7% | -171.1% | 126.0% |
| ROCE % | -0.5% | -18.1% | 165.2% | -171.1% | 126.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ESLA
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
EMERYVILLE, Calif., August 03, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoim…
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
EMERYVILLE, Calif., July 29, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmu…
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
EMERYVILLE, Calif., July 24, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmu…
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most significant unresolved challenges in cell…
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Initiating Coverage We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with a valuation of $12.00 per share and a thesis centered on the potential for the c…
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL
By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell Non-Hodgkin Lym…
ESLA — Frequently Asked Questions
What is the current share price of ESLA?
As of 2026-08-05 17:25 PDT, ESLA trades at $0.75 on NASDAQ/NYSE. Its 52-week range is $0.70 to $3.05.
What is the P/E ratio of ESLA?
ESLA trades at a trailing price-to-earnings (P/E) ratio of -2.14.
What is the return on equity (ROE) of ESLA?
ESLA has a return on equity (ROE) of 126.02%. Its return on capital employed (ROCE) is 126.01%.
Is ESLA a good stock to buy?
This page provides a data-driven analysis of ESLA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.